Overview

IM and Oral in Acute Exacerbation of Schizophrenia (BIZET Study)

Status:
Completed
Trial end date:
2005-11-01
Target enrollment:
Participant gender:
Summary
To evaluate efficacy and tolerability of Ziprasidone IM and oral in agitated patients with acute exacerbation of schizophrenia
Phase:
Phase 3
Details
Lead Sponsor:
Pfizer
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Treatments:
Ziprasidone